Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC
HONG KONG, Feb. 6, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) evaluating ivonescimab, its...
MoEngage's Email Benchmarks Report Reveals a Shift in Personalization Trends for 2025
Analysis of 17.3 billion marketing emails reveals behavior-based emails can achieve up to 300.7x conversion rates compared to non-personalized emails SAN FRANCISCO, Jan. 15, 2025 /PRNewswire/ -- MoEngage, an insights-led cross-channel customer...